These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

930 related items for PubMed ID: 11316141

  • 1. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
    Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, Geis GS.
    Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
    [Abstract] [Full Text] [Related]

  • 2. A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years.
    Goldstein JL, Aisenberg J, Lanza F, Schwartz H, Sands GH, Berger MF, Pan S.
    Clin Ther; 2006 Mar; 28(3):340-51. PubMed ID: 16750449
    [Abstract] [Full Text] [Related]

  • 3. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.
    Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, Verburg KM, Geis GS.
    Am J Gastroenterol; 2000 Jul; 95(7):1681-90. PubMed ID: 10925968
    [Abstract] [Full Text] [Related]

  • 4. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
    Goldstein JL, Cryer B, Amer F, Hunt B.
    Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
    [Abstract] [Full Text] [Related]

  • 5. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC, Chu KM, Hui WM, Wong BC, Hu WH, Wong WM, Chan AO, Wong J, Lam SK.
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [Abstract] [Full Text] [Related]

  • 6. Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis.
    Cheung R, Cheng TT, Dong Y, Lin HY, Lai K, Lau CS, Feng H, Parsons B.
    Int J Rheum Dis; 2010 May; 13(2):151-7. PubMed ID: 20536600
    [Abstract] [Full Text] [Related]

  • 7. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
    Bensen WG, Zhao SZ, Burke TA, Zabinski RA, Makuch RW, Maurath CJ, Agrawal NM, Geis GS.
    J Rheumatol; 2000 Aug; 27(8):1876-83. PubMed ID: 10955327
    [Abstract] [Full Text] [Related]

  • 8. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor.
    Goldstein JL, Lowry SC, Lanza FL, Schwartz HI, Dodge WE.
    Aliment Pharmacol Ther; 2006 May 15; 23(10):1489-98. PubMed ID: 16669964
    [Abstract] [Full Text] [Related]

  • 9. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
    Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, Andrade-Ortega L, Wallemark C, Agrawal NM, Eisen GM, Stenson WF, Triadafilopoulos G, SUCCESS-I Investigators.
    Am J Med; 2006 Mar 15; 119(3):255-66. PubMed ID: 16490472
    [Abstract] [Full Text] [Related]

  • 10. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG, Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators.
    Arch Intern Med; 2005 Jan 24; 165(2):161-8. PubMed ID: 15668361
    [Abstract] [Full Text] [Related]

  • 11. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS.
    Scand J Rheumatol Suppl; 1999 Jan 24; 109():31-7. PubMed ID: 10422544
    [Abstract] [Full Text] [Related]

  • 12. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
    Varas-Lorenzo C, Maguire A, Castellsague J, Perez-Gutthann S.
    Pharmacoepidemiol Drug Saf; 2007 Apr 24; 16(4):366-76. PubMed ID: 16897817
    [Abstract] [Full Text] [Related]

  • 13. The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial.
    Bias P, Buchner A, Klesser B, Laufer S.
    Am J Gastroenterol; 2004 Apr 24; 99(4):611-8. PubMed ID: 15089890
    [Abstract] [Full Text] [Related]

  • 14. Incidence of outpatient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and naproxen in an insured population in the United States.
    Goldstein JL, Zhao SZ, Burke TA, Palmer R, von Allmen H, Henderson SC.
    Am J Gastroenterol; 2003 Dec 24; 98(12):2627-34. PubMed ID: 14687808
    [Abstract] [Full Text] [Related]

  • 15. Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo-controlled, double-blind 2-week study.
    Sakamoto C, Kawai T, Nakamura S, Sugioka T, Tabira J.
    Aliment Pharmacol Ther; 2013 Feb 24; 37(3):346-54. PubMed ID: 23216412
    [Abstract] [Full Text] [Related]

  • 16. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
    Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, Isakson PC, Verburg KM, Yu SS, Zhao WW, Geis GS.
    JAMA; 1999 Nov 24; 282(20):1921-8. PubMed ID: 10580457
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct 24; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [Abstract] [Full Text] [Related]

  • 18. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS.
    JAMA; 2000 Sep 13; 284(10):1247-55. PubMed ID: 10979111
    [Abstract] [Full Text] [Related]

  • 19. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial.
    Pavelka K, Recker DP, Verburg KM.
    Rheumatology (Oxford); 2003 Oct 13; 42(10):1207-15. PubMed ID: 12810937
    [Abstract] [Full Text] [Related]

  • 20. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
    Daniels S, Robbins J, West CR, Nemeth MA.
    Clin Ther; 2009 Jun 13; 31(6):1192-208. PubMed ID: 19695387
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.